The ASL Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, designed for targeted disruption of the ASL gene. This model enables loss-of-function studies of argininosuccinate lyase (ASL), a key urea cycle enzyme, with the polyclonal pool providing heterogeneous mutations ideal for versatile gene function analysis without clonal limitations. CRISPR/Cas9-mediated gene disruption ensures efficient, site-specific targeting for reproducible outcomes in functional genomics.
The A-549 host cell line, originally derived from a human lung adenocarcinoma, is widely employed as an alveolar epithelial cell model. These cells are characterized by their ability to form polarized monolayers, produce surfactant, and maintain pulmonary barrier functions, making them highly relevant for respiratory biology research. Additionally, A-549 cells express various transporters and metabolic enzymes, enabling investigations into nutrient utilization and metabolic reprogramming in cancer. Their epithelial origin also permits studies of epithelial-to-mesenchymal transition (EMT) and tumor metastasis, expanding the utility of this knockout model to cancer biology.
Argininosuccinate lyase catalyzes the hydrolysis of argininosuccinate into arginine and fumarate, a pivotal step in the urea cycle that links nitrogen disposal to cellular bioenergetics and biosynthetic pathways. ASL function is tightly regulated by upstream factors such as glucocorticoid signaling, hepatocyte nuclear factor 4 alpha (HNF4A), and feedback from arginine substrate availability. The enzyme interacts physically with argininosuccinate synthetase 1 (ASS1) and nitric oxide synthase 3 (NOS3), forming part of a larger urea cycle enzyme complex that includes ornithine transcarbamylase (OTC) and carbamoyl phosphate synthetase 1 (CPS1). The arginine produced by ASL serves as the sole substrate for nitric oxide synthases, fueling nitric oxide signaling, and also feeds into polyamine and creatine biosynthesis. Moreover, fumarate released by ASL enters the tricarboxylic acid (TCA) cycle, thereby integrating urea cycle activity with mitochondrial respiration.
In the A-549 adenocarcinoma context, ASL knockout disrupts arginine metabolism, sensitizing cells to arginine deprivation and altering downstream signaling networks. This is particularly relevant for cancer metabolism studies, as many tumors exhibit urea cycle dysregulation and rely on extracellular arginine for survival. The loss of ASL may impair nitric oxide production, impacting endothelial-like functions that A-549 cells can exhibit, and potentially influencing tumor angiogenesis and microenvironmental interactions. Additionally, fumarate accumulation or depletion could affect TCA cycle flux and associated metabolic vulnerabilities. Thus, this knockout model offers a physiologically relevant platform to dissect the metabolic dependencies of lung adenocarcinoma cells.
Applications include metabolic profiling via ammonia quantification, arginine/urea measurement, and nitric oxide detection (Griess assay); protein and gene expression analysis by Western blotting and RT-qPCR; and functional assays such as cell viability under arginine starvation and metabolomics. The model is suited for drug screening in argininosuccinic aciduria, studying arginine deprivation in cancer, and exploring citrulline-nitric oxide cycle roles in hypertension and endothelial dysfunction. For technical support, contact Ascent Research.
